Search
                    Macular Degeneration Clinical Trials
A listing of 9  Macular Degeneration  clinical trials  actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
            1 - 9 of 9
        
        
    
                There are currently 9 active clinical trials seeking participants for Macular Degeneration research studies. The states with the highest number of trials for Macular Degeneration participants are California, Texas, Florida and Arizona.
            
                Featured Trial
                
                Healthy Participants Needed (Colonoscopy + Cancer Screening)
            
        Recruiting
            
        Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
    
    
                            Conditions: 
                                    
        
            
                        Healthy
                    
                                    
                        Healthy Volunteers
                    
                                    
                        Healthy Subjects
                    
                                    
                        Healthy Volunteer
                    
                                    
                        Healthy Participants
                    
                                    Featured Offer
                
                Lose Weight with GLP-1 Medications
            
        Recruiting
            
        Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®. 
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
    GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
                            Conditions: 
                                    
        
            
                        Overweight
                    
                                    
                        Overweight and Obesity
                    
                                    
                        Obesity
                    
                                    
                        Weight Loss
                    
                                    
                        Morbid Obesity
                    
                                    Featured Trial
                
                Stroke Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Stroke
    
    
                            Conditions: 
                                    
        
            
                        Stroke
                    
                                    Featured Trial
                
                Chronic Kidney Disease (CKD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Chronic Kidney Disease (CKD)
    
    
                            Conditions: 
                                    
        
            
                        Chronic Kidney Disease (CKD)
                    
                                    
                
                                    A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy
                                
            
            
        Recruiting
                            
            
                This study is for people who have geographic atrophy due to age-related macular degeneration (AMD). AMD happens when the macula, the light-sensitive layer at the back of the eye called the retina, becomes damaged and causes a person's central vision to worsen. Geographic atrophy is an advanced form of AMD where cells in the retina waste away and die. Over time this can lead to permanent loss of vision.
Avacincaptad pegol can help slow down the worsening or progression of geographic atrophy. Ava...  Read More             
        
        
    Gender:
                ALL
            Ages:
                All
            Trial Updated:
                08/20/2025
            
            Locations: Retinal Consultants of AZ, Phoenix, Arizona  +41 locations         
        
        
            Conditions: Geographic Atrophy, Macular Degeneration
        
            
        
    
                
                                    A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to assess the long-term safety and tolerability after an intravitreal injection (a shot of medicine into the eye) of JNJ-81201887 administered in parent clinical studies.             
        
        
    Gender:
                ALL
            Ages:
                60 years and above
            Trial Updated:
                08/14/2025
            
            Locations: Retina Associates Southwest PC, Tucson, Arizona  +76 locations         
        
        
            Conditions: Geographic Atrophy, Macular Degeneration
        
            
        
    
                
                                    Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration
                                
            
            
        Recruiting
                            
            
                This is a first in-human study to investigate the safety, tolerability and efficacy of zifibancimig administered through intravitreal (IVT) injections and via the Port Delivery (PD) implant in participants with neovascular age-related macular degeneration (nAMD).             
        
        
    Gender:
                ALL
            Ages:
                50 years and above
            Trial Updated:
                08/04/2025
            
            Locations: Barnet Dulaney Perkins Eye Center, Mesa, Arizona  +52 locations         
        
        
            Conditions: Macular Degeneration
        
            
        
    
                
                                    A Prospective Observational Study to Assess the Reliability and Validity of the MLSDT
                                
            
            
        Recruiting
                            
            
                The goal of this observational study is to assess the reliability and validity of the 9-object MLSDT for evaluation of participants with moderate to severe vision impairment when tested without a wearable low-vision magnifying aid (eGlasses) and then with eGlasses. These results will be compared to ETDRS testing results for the same participants without eGlasses and then with eGlasses. Two cohorts will consist of participants who have vision loss due to STGD or geographic atrophy (GA) due to age...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                03/18/2025
            
            Locations: Retina of North Texas,, Dallas, Texas         
        
        
            Conditions: Macular Degeneration, Geographic Atrophy, Stargardt Disease
        
            
        
    
                
                                    Stem Cell Ophthalmology Treatment Study II
                                
            
            
        Recruiting
                            
            
                This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                03/17/2025
            
            Locations: MD Stem Cells, Westport, Connecticut  +3 locations         
        
        
            Conditions: Retinal Disease, Age-Related Macular Degeneration, Retinitis Pigmentosa, Stargardt Disease, Optic Neuropathy, Nonarteritic Ischemic Optic Neuropathy, Optic Atrophy, Optic Nerve Disease, Glaucoma, Leber Hereditary Optic Neuropathy, Blindness, Vision Loss Night, Vision Loss Partial, Vision, Low, Retinopathy, Maculopathy, Macular Degeneration, Retina Atrophy
        
            
        
    
                
                                    NYSCF Scientific Discovery Biobank
                                
            
            
        Recruiting
                            
            
                The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate diverse disease research using cells from the body (such as skin or blood cells) to make stem cells and other types of cells, conduct research on the samples, perform genetic testing, and store the samples for future use.
Through this research, researchers hope to identify future treatments or even cures for the major diseases of our time.             
        
        
    Gender:
                ALL
            Ages:
                30 days and above
            Trial Updated:
                02/27/2025
            
            Locations: New York Stem Cell Foundation Research Institute, New York, New York         
        
        
            Conditions: ALS, Amyotrophic Lateral Sclerosis, Alzheimer Disease, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Batten Disease, Corticobasal Degeneration, Dementia, Frontotemporal Dementia, Huntington Disease, Lewy Body Disease, Multiple Sclerosis, Multiple System Atrophy, Parkinson Disease, Parkinson's Disease and Parkinsonism, Progressive Supranuclear Palsy, INAD, Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Macular Degeneration, Ovarian Cancer, Cervical Cancer, Uterine Cancer, Vaginal Cancer, Vulvar Cancer, PTSD, Post Traumatic Stress Disorder
        
            
        
    
                
                                    Factors in Learning and Plasticity: Healthy Vision
                                
            
            
        Recruiting
                            
            
                A greater understanding of plasticity after central vision loss can inform new therapies for treating low vision and has the potential to benefit millions of individuals suffering from low vision. The treatment of low vision is particularly relevant to the mission of the National Eye Institute (NEI) to support research on visual disorders, mechanisms of visual function, and preservation of sight. The comparison of different training and outcome factors is in line with the National Institute of M...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 30 years
            Trial Updated:
                02/18/2025
            
            Locations: UAB, Birmingham, Alabama  +1 locations         
        
        
            Conditions: Central Visual Impairment, Macular Degeneration
        
            
        
    
                
                                    Factors in Learning and Plasticity: Macular Degeneration
                                
            
            
        Recruiting
                            
            
                A greater understanding of plasticity after central vision loss can inform new therapies for treating low vision and has the potential to benefit millions of individuals suffering from low vision. The treatment of low vision is particularly relevant to the mission of the NEI to support research on visual disorders, mechanisms of visual function, and preservation of sight. The comparison of different training and outcome factors is in line with the NIMH RDOC framework and studies in an aging popu...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 89 years
            Trial Updated:
                02/18/2025
            
            Locations: UAB, Birmingham, Alabama         
        
        
            Conditions: Central Visual Impairment, Macular Degeneration
        
            
        
    
                
                                    Scotoma Perimetry Oculomotor Training
                                
            
            
        Recruiting
                            
            
                The proposed research is relevant to public health because a greater understanding of plasticity after central vision loss can inform new therapies for treating low vision and has potential to benefit millions of individuals suffering from low vision. The treatment of low vision is particularly relevant to the mission of the NEI to support research on visual disorders, mechanisms of visual function and preservation of sight.
Declines in vision are particularly common in older adults and thus in...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 89 years
            Trial Updated:
                01/21/2025
            
            Locations: UAB, Birmingham, Alabama         
        
        
            Conditions: Macular Degeneration, Central Visual Impairment
        
            
        
    1 - 9 of 9
            
            
        